Anocca

Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer

Financing supports execution of early-stage clinical trials for Anocca’s lead programme VIDAR-1, powered by the Company’s leading-edge R&D platform, to target pancreatic cancer VIDAR-1 is the first non-viral gene-edited TCR-T cell therapy in Europe with recruitment open. 18 August 2025 -- Södertälje, Sweden -- Anocca, a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK...

Anocca AB licenses gene editing technology from EmendoBio Inc

Enabling Technology Supports the Development of Anocca’s Deep Pipeline of TCR-T therapeutics 14 March 2024 – New York, US and Södertälje, Sweden – Anocca AB (Anocca), a leading T-cell receptor-engineered T-cell (TCR-T) cellular therapeutics company, and EmendoBio Inc. (EmendoBio), a nuclease discovery and gene editing therapeutics company, today announced a non-exclusive licensing agreement for the...
Forskargatan 20C 151 36 Södertälje, Sweden

+46 (0)8 410 807 50